Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals has launched Empagliflozin (Glempa) and its fixed-dose combinations in India, offering new treatment options for type 2 diabetes patients with cardiovascular risks.

• HPK1 inhibition is emerging as a strategy to enhance T-cell functionality and improve immunotherapy efficacy in solid tumors, with several inhibitors in early-phase trials. • NDI-101150, a novel oral HPK1 inhibitor, has demonstrated early clinical efficacy, including a complete response in renal cell carcinoma, as both a monotherapy and in combination with pembrolizumab. • Combination therapies involving HPK1 inhibitors like BGB-15025 with checkpoint inhibitors such as tislelizumab are showing early efficacy signals, warranting further investigation. • Several HPK1 inhibitors, including GRC 54276 and CFI-402411, are in phase 1/2 trials, exploring their potential as monotherapies and in combination with pembrolizumab across various advanced solid tumors.